## Neelanjana Ray

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11588473/publications.pdf

Version: 2024-02-01

623188 1058022 14 779 14 14 citations g-index h-index papers 14 14 14 995 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. Journal of Antimicrobial Chemotherapy, 2014, 69, 573-581.	1.3	56
2	Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors. Antimicrobial Agents and Chemotherapy, 2013, 57, 4172-4180.	1.4	67
3	Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 7-15.	0.9	38
4	Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects. Journal of Infectious Diseases, 2012, 206, 1002-1011.	1.9	92
5	<i>In Vitro</i> Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068. Antimicrobial Agents and Chemotherapy, 2012, 56, 3498-3507.	1.4	118
6	Study of Andes virus entry and neutralization using a pseudovirion system. Journal of Virological Methods, 2010, 163, 416-423.	1.0	40
7	HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry. AIDS Research and Human Retroviruses, 2010, 26, 13-24.	0.5	54
8	Maraviroc in the treatment of HIV infection. Drug Design, Development and Therapy, 2009, 2, 151.	2.0	21
9	HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide. Journal of Virology, 2009, 83, 2989-2995.	1.5	52
10	Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology, 2009, 387, 296-302.	1.1	39
11	Baseline Resistance of Primary Human Immunodeficiency Virus Type 1 Strains to the CXCR4 Inhibitor AMD3100. Journal of Virology, 2008, 82, 11695-11704.	1.5	17
12	Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors. Journal of Virology, 2007, 81, 3240-3250.	1.5	68
13	Cyclooxygenase-1 and -2 Are Required for Production of Infectious Pseudorabies Virus. Journal of Virology, 2004, 78, 12964-12974.	1.5	37
14	Transcriptional Response of a Common Permissive Cell Type to Infection by Two Diverse Alphaherpesviruses. Journal of Virology, 2004, 78, 3489-3501.	1.5	80